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In standard-risk acute promyelocytic leukemia, recent results haveshown that all-trans retinoic acid plus arsenic trioxide combinationsare at least as effective as classical all-trans retinoic acid plus anthracy-
cline-based chemotherapy while being less myelosuppressive. However,
the role of frontline arsenic trioxide is less clear in higher-risk acute
promyelocytic leukemia, and access to arsenic remains limited for front-
line treatment of standard-risk acute promyelocytic leukemia in many
countries. In this randomized trial, we compared arsenic, all-trans
retinoic acid and the “classical” cytarabine for consolidation treatment
(after all-trans retinoic acid and chemotherapy induction treatment) in
standard-risk acute promyelocytic leukemia, and evaluated the addition
of arsenic during consolidation in higher-risk disease. Patients with
newly diagnosed acute promyelocytic leukemia with a white blood cell
count <10x109/L, after an induction treatment consisting of all-trans
retinoic acid plus idarubicin and cytarabine, received consolidation
chemotherapy with idarubicin and cytarabine, arsenic or all-trans
retinoic acid. Patients with a white blood cell count >10x109/L received
consolidation chemotherapy with or without arsenic. Overall, 795
patients with acute promyelocytic leukemia were enrolled in this trial.
Among those with standard-risk acute promyelocytic leukemia (n=581),
the 5-year event-free survival rates from randomization were 88.7%,
95.7% and 85.4% in the cytarabine, arsenic and all-trans retinoic acid
consolidation groups, respectively (P=0.0067), and the 5-year cumulative
incidences of relapse were was 5.5%, 0%  and 8.2%. (P=0.001). Among
those with higher-risk acute promyelocytic leukemia (n=214), the 5-year
event-free survival rates were 85.5% and 92.1% (P=0.38) in the
chemotherapy and chemotherapy plus arsenic groups, respectively, and
the corresponding 5-year cumulative incidences of relapse were 4.6%
and 3.5% (P=0.99). Given the prolonged myelosuppression that
occurred in the chemotherapy plus arsenic arm, a protocol amendment
excluded cytarabine during consolidation cycles in the chemotherapy
plus arsenic group,  resulting in no increase in  relapse. Our results there-
fore advocate systematic introduction of arsenic in the first-line treat-
ment of acute promyelocytic leukemia, but probably not concomitantly
with intensive chemotherapy, a situation in which we found myelosup-
pression to be significant. (ClinicalTrials.gov Identifier: NCT00378365)
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ABSTRACT
Introduction
Acute promyelocytic leukemia (APL) is a specific subtype
of acute myeloid leukemia (AML) characterized by its mor-
phology, the presence of t(15;17), and marked sensitivity to
the differentiating effect of all-trans retinoic acid (ATRA)
and the pro-apoptotic effect of arsenic trioxide (ATO).1 The
combination of ATRA and anthracycline-based chemother-
apy has been the mainstay of the treatment of newly diag-
nosed APL over the last two decades.2–4 Published results
have shown that cytarabine (cytosine arabinoside, AraC)
could be omitted from chemotherapy in standard-risk APL
[i.e., with a baseline white blood cell count (WBC)
<10x109/L] but appeared to be useful in high-risk APL (with
a WBC >10x109/L), possibly at high doses, to reduce the
incidence of relapse.5 A beneficial role for prolonged main-
tenance treatment with continuous low-dose chemothera-
py (6-mercaptopurine and methotrexate) and intermittent
ATRA was also suggested, especially in high-risk APL, fol-
lowing in particular randomized results from our group,5,6
and from a recent meta-analysis7 of several trials. With
regards to anthracyclines, at least one study suggested that
idarubicin gave better results than daunorubicin,8 while
non-randomized studies suggested a potential benefit of
adding ATRA during consolidation cycles, at least if AraC
was omitted.2,4
Recently, however, ATO has been demonstrated to have
pronounced efficacy in newly diagnosed APL. In particular,
it was shown in two large randomized trials that the com-
bination of ATO and ATRA without chemotherapy was at
least equal and, with longer term follow-up, even superior
to ATRA plus chemotherapy combinations in standard-risk
APL.9,10,11 In high-risk APL, ATO plus ATRA combinations,
with very limited added chemotherapy, also appear very
promising,10,12 and are currently being compared with the
conventional ATRA chemotherapy approach in random-
ized trials.
When the APL 2006 trial was launched, ATO was mainly
considered as an adjunct to ATRA  chemotherapy combina-
tions in the first-line treatment of APL, aimed at reducing
the relapse rate (especially in high-risk APL) and/or dimin-
ishing  the amount of chemotherapy administered (espe-
cially in standard-risk APL).
Based on the results of the APL 2006 trial, reported here,
we evaluated the role of ATO in the treatment of standard-
and high-risk APL, in addition to the “classical” ATRA plus
chemotherapy backbone regimens. 
Methods
Patients
Between 2006 and 2013, patients from French, Belgian and
Swiss centers with documented (by cytogenetics and or molecular
biology), newly diagnosed APL who were aged 70 years or less
were eligible for inclusion in the APL 2006 trial, after giring
informed consent. The trial was approved by local ethical commit-
tees (ClinicalTrials.gov Identifier: NCT00378365). Eligibility crite-
ria in this trial were a morphological diagnosis of APL based on
French-American-British criteria and no contraindication to inten-
sive chemotherapy. No minimal performance status was required
and patients with therapy-related APL could be enrolled.
Induction treatment consisted of ATRA 45 mg/m2/day until
complete remission with idarubicin 12 mg/m2/day for 3 days and
AraC 200 mg/m2/day for 7 days starting on day 3. 
Patients with a baseline WBC <10x109/L who achieved a com-
plete remission were randomized for consolidation between three
groups given treatment containing AraC, ATO or ATRA. The
AraC group (standard group) received a first consolidation course
with idarubicin 12 mg/m2/day for 3 days and AraC 200 mg/m2/day
for 7 days, a second consolidation course with idarubicin 9
mg/m2/day for 3 days and AraC 1 g/m2/12 h for 4 days, and main-
tenance therapy for 2 years with intermittent ATRA 15 days/3
months and continuous treatment with 6 mercaptopurine (90
mg/m2/day orally) and methotrexate (15 mg/m2/week orally). 
The ATO and ATRA groups received the same treatment as the
AraC group, but AraC was replaced by, respectively, ATO 0.15
mg/kg/day on days 1 to 25 and ATRA 45 mg/m2/day on days 1 to
15 for both consolidation courses. The rationale for the ATRA con-
solidation treatment was based on results of a Spanish PETHEMA
group trial, suggesting that AraC could be omitted from
chemotherapy consolidation cycles in standard-risk APL, and that
there could be a benefit from adding ATRA to consolidation cycles.
The use of prolonged maintenance treatment was based on our
previous results in a randomized phase III trial supporting the
interest of this approach in reducing relapses after a conventional
ATRA chemotherapy regimen.
Patients with a baseline WBC >10x109/L were randomized to
consolidation with either chemotherapy or chemotherapy com-
bined with ATO. The chemotherapy group received a first con-
solidation course with idarubicin 12 mg/m2/day for 3 days and
AraC 200 mg/m2/day for 7 days, a second consolidation course
with idarubicin 9 mg/m2/day for 3 days and AraC 1 g/m2/12 h for
4 days, and 2-year maintenance therapy with intermittent ATRA
and continuous 6-mercaptopurine plus methotrexate. The
chemotherapy plus ATO group received the same treatment
except that ATO 0.15 mg/kg/day was added from day 1 to day
25 during both consolidation courses. After a first interim analy-
sis in September 2010 on data from 81 patients,  AraC was delet-
ed from consolidation cycles of the chemotherapy plus ATO
group. 
Treatment of coagulopathy during the induction phase was
based on platelet support to maintain the platelet count at a level
greater than 50x109/L until the disappearance of the coagulopathy.
The use of heparin, tranexamic acid, fresh-frozen plasma, and fib-
rinogen transfusions was optional, according to each center's poli-
cy.
Prophylaxis and treatment of ATRA syndrome consisted of dex-
amethasone 10 mg/12 h given intravenously for at least 3 days if
the WBC was above 10x109/L (before or during treatment with
ATRA) or at the earliest sign of the ATRA syndrome (dyspnea,
lung infiltrates, pleural effusion, unexplained renal failure). In the
absence of rapid improvement of symptoms (within 24 h), ATRA
was transiently stopped until clinical control was obtained.
Statistical methods
The primary endpoint was event-free survival from the time of
achieving complete remission. Relapse, survival, side effects of the
treatment and duration of hospitalization were secondary end-
points.
Analyses were performed on a modified intent-to-treat princi-
ple, excluding only diagnostic errors and withdrawals of consent.
Censored endpoints were estimated by the nonparametric Kaplan-
Meier method13 and then compared between randomized groups
by the log-rank test.  In estimating relapses, we took into account
competing risks, i.e., deaths in first complete remission, using
cumulative incidence curves and then compared results using the
Gray test, whereas a cause-specific Cox model was used to esti-
mate cause-specific hazard ratios.14 The type I error was fixed at
the 5% level. All tests were two-tailed. Statistical analyses were
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performed using SAS 9.1 (SAS Inc, Cary, NC, USA) and R software
packages.
Here we present the results based on all patients included in the
trial and data collected before June, 2017.
Results
Eight-hundred and seven patients were included in the
trial. The diagnosis of APL could be confirmed in 795 of the
patients who had t(15;17) and/or a PML-RAR rearrange-
ment. The remaining 12 patients were excluded as diagnos-
tic errors. The further analyses only dealt with the 795
patients with a confirmed diagnosis of APL who gave their
consent to participation in the study and comprised 581
patients with standard-risk APL and 214 with high-risk
APL.
Standard-risk acute promyelocytic leukemia
Of the 581 patients with standard-risk APL; 570 (98.1%)
achieved a complete remission; the others died early. Forty-
three patients were not randomized for consolidation treat-
ment, including the 11 patients who did not achieve a com-
plete remission, 15 due to adverse events, 12 due to the
patients’ decision and five for other reasons (Figure 1).
Five-hundred and thirty-eight patients were randomized
to different consolidation treatment (178, 180 and 180 in
the AraC, ATO and ATRA arms, respectively). Pre-treat-
ment characteristics were well-balanced between the three
consolidation groups (Table 1). 
Overall, 8, 0, and 14 patients relapsed (P=0.001) and 11, 5,
and 11 patients (P=0.28) died in complete remission in the
AraC, ATO and ATRA consolidation groups, respectively.
Causes of death in complete remission were sepsis (n=2),
hemorrhage (n=16), AML/myelodysplastic syndrome
(MDS) (n=2), other (n=7). Overall, five patients developed
AML/MDS including two, one and two patients treated in
the AraC, ATO and ATRA arms, respectively. 
Five-year event-free survival rates from randomization
were 88.7%, 95.7% and 85.4% in the AraC, ATO and
ATRA consolidation groups, respectively (P=0.0067). The
5-year cumulative incidences of relapse were 5.5%, 0% and
8.2% (P=0.001) and the 5-year overall survival rates were
93.6%, 95.7% and 91.9% (P=0.349) in the AraC, ATO and
ATRA consolidation groups, respectively (Figure 2). 
The median times to an absolute neutrophil count
>1x109/L after the first consolidation course were 23.5, 22.8
and 18 days in the AraC, ATO and ATRA groups, respec-
tively (P<0.0001). Similarly, the times to an absolute neu-
trophil count >1x109/L after the second consolidation
course were 23.3, 18.2 and 13.8 days (P<0.0001). The medi-
an durations of hospitalization after the first and the second
consolidation courses were 31.5, 32.2, and 19.5 days
(P<0.0001) and 28.2, 29.9, and 16.5 days in the AraC, ATO
and ATRA group, respectively (P<0.0001).
High-risk acute promyelocytic leukemia
Of the 214 patients with high-risk APL, 205 (95.7%)
achieved a complete remission, seven (3.2%) died early (1
from bleeding, 3 from thrombosis, 1 from sepsis and 2 from
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Figure 1. Consort diagrams. (A) Patients with a
white blood cell count <109/L; (B) Patients with
a white blood cell count >109/L. APL: acute
promyelocytic leukemia; ARAC: cytarabine; ATO:
arsenic trioxide; ATRA: all-trans retinoic acid.
A
B
other causes) and two (0.9%) had resistant leukemia.
Seventeen patients were not randomized to consolidation
treatment, including the nine patients who did not achieve
a complete remission, three due to adverse events and five
consequent to the patients’ decision.
One hundred and ninety-seven patients were random-
ized to consolidation therapy, 99 in the chemotherapy
group and 98 in the chemotherapy plus ATO groups. Pre-
treatment characteristics were well balanced between the
two groups (Table 2). With a median follow-up of 52
months, eight patients (4 in the chemotherapy group versus
4 in the chemotherapy plus ATO group) had relapsed lead-
ing to 5-year cumulative incidence rates of 4.6% [95% con-
fidence interval (95% CI: 1.5; 10.6) and 3.5% (95% CI: 0.9;
9.2), P=0.99] and 13 patients had died in complete remis-
sion including nine in the chemotherapy arm and four in
the chemotherapy plus arm (P=0.98). One patient, random-
ized to the chemotherapy plus ATO arm, developed
AML/MDS. The 5-year overall survival rates were 90% and
93% in the chemotherapy and chemotherapy plus ATO
groups, respectively (P=0.62), while the corresponding 5-
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Figure 2. Event-free survival,
cumulative incidence of
relapse and overall survival
in patients with standard-
risk acute promyelocytic
leukemia. ARAC: cytarabine;
ATO: arsenic trioxide; ATRA:
all-trans retinoic acid; CR:
complete remission.
Table 1. Baseline characteristics of the patients aged <70 years with
standard-risk acute promyelocytic leukemia.
Median [Q1-Q3]               AraC Arm              ATO Arm            ATRA Arm
                                           N=178                N=180              N=180
Age (years)                                 45.4                          49.4                        50.5
                                               [32.45; 55.95]          [38.85; 57.8]          [38.4; 60.8]
WBC (x109/L)                               1.3                            1.4                         1.51
                                                  [0.8; 2.3]              [0.95; 2.615]           [0.8; 3.45]
Platelets(x109/L)                44.5 [25; 71]          46 [20.75; 77]         42 [20; 68]
Fibrinogen (g/L)                1.8 [1.2; 2.7]          1.7 [1.1; 2.65]        1.8 [1.2; 2.6]
%M3v                                             3%                            8%                          5%
Previous cancer                         12%                          12%                         9%
QI: first quartile; Q3: third quartile; AraC: cytarabine; ATO: arsenic trioxide; ATRA: all-
trans retinoic acid; WBC: white blood cells; %M3v: microgranular variant (%).
Table 2. Baseline characteristics of the patients aged less than 70
years with high-risk acute promyelocytic leukemia.
Median [Q1-Q3]                               CT Arm                   CT + ATO Arm
                                                          n=99                           n=98
Age (years)                                                 39.2                                   45.0
                                                                [29.6 ; 54.1]                    [33.85; 58.9]
WBC (x109/L)                                               23.7                                    19.7
                                                                [14.7; 37.3]                       [13; 34.2]
Platelets (x109/L)                                        26.5                                     32 
                                                                [13.3; 47.8]                         [18; 51]
Fibrinogen (g/L)                                         1.3                                     1.3 
                                                                  [1.1; 1.7]                          [0.9; 1.8]
%M3v                                                             34%                                   28%
% Previous cancer                                      8%                                    11%
QI: first quartile; Q3: third quartile; CT: chemotherapy; ATO: arsenic trioxide; WBC: white
blood cells; %M3v:  microgranular variant (%).
year event-free rates were 85.5% and 92.1% (P=0.38)
(Figure 3). 
Excluding AraC (after the protocol amendment) from the
consolidation cycles in the chemotherapy plus ATO group
did not increase the 5-year cumulative incidence of relapse
(4.6% in the chemotherapy  arm, 5.3% in the chemothera-
py plus ATO with AraC arm and 2.7% in the chemothera-
py plus ATO without AraC arm, P=0.61). On the other
hand, excluding AraC from consolidation cycles in the
chemotherapy plus ATO arm significanty reduced  myelo-
suppression: the median times to an absolute neutrophil
count >1x109/L after the second consolidation course were
22, 25 and 18 days in, respectively, the chemotherapy arm,
the chemotherapy plus ATO with AraC arm, and the
chemotherapy plus ATO without AraC arm (P<0.001),
while the median times to a platelet count >50x109/L were
24, 26 and 18 days (P<0.001). Similarly, the median dura-
tions of hospitalization after the first and the second consol-
idation courses were 29 days, 34 days, and 33 days
(P<0.0001) and 28 days, 32 days and 31 days  (P=0.0005),
respectively.
Discussion
The main results of this study are that, in standard-risk
APL, addition of ATO to a “classical” ATRA chemotherapy
regimen further reduces the incidence of relapse and that, in
high-risk APL, AraC (including high-dose AraC) can be
replaced by ATO without increasing the relapse risk and
with more limited myelosuppression, thus potentially
reducing the risk of death in complete remission.
A first finding was the very high complete remission rate
obtained in the APL 2006 trial, both in standard-risk and
high-risk APL (98.1% and 95.7%, respectively), even
though patients could be included up to the age of 70.
Recent reports have suggested that, even in the ATRA era,
early death rates could be as high as 15% to 20% in “real-
life” APL patients.15–19 On the other hand, we previously
published that, during the 2006 to 2011 period, 75% of the
patients in the 17 French largest centers participating in the
APL 2006 trial could be included in the trial, while 25%
could not, mainly based on age, major comorbidities or
direct admission to an intensive care unit.15 The overall
complete remission rate was 91.4% and the overall rate of
early death was 8.6%. All studies suggest that, if APL is sus-
pected and before the diagnosis is confirmed, the immedi-
ate institution of ATRA treatment can reduce the risk of
early death. Intensive platelet support during induction
treatment can probably also contribute to reducing the risk
of early death, particularly in patients with high-risk APL.
In the APL 2006 trial, in standard-risk APL patients aged
less than 70 years of age, our aim was to show that by sub-
stituting ATO or ATRA for AraC during consolidation
cycles, we would not increase the relapse rate, but would
reduce myelosuppression, thereby potentially reducing the
incidence of deaths in complete remission, which was 5%
in our previous experience with AraC-containing consoli-
dation cycles (at a conventional dose for the first consolida-
tion cycle, and intermediate dose for the second). The
ATRA and chemotherapy regimen chosen appeared to be
an “optimal” regimen, using in particular high cumulative
doses of anthracyclines, idarubicin rather than daunoru-
bicin (as the latter may lead to more relapses8), AraC during
consolidation and prolonged maintenance treatment with
6-mercaptopurine, methotrexate and intermittent ATRA,
which may also contribute to reducing the relapse rate.7
This reference treatment proved effective, as the incidence
of relapse  after 5 years was only 5.5%.
Substituting ATRA for AraC did not significantly increase
the relapse rate (8.2% at 5 years, compared to 5.5% in the
AraC group) , but the replacement significantly reduced the
time to recovery from neutropenia after the first and second
consolidation cycles, and the duration of hospitalization
during those two consolidation cycles. It did not reduce the
incidence of deaths in complete remission, but among the
six, six and five deaths in complete remission occurring in
the three consolidation groups, only two in each arm were
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Figure 3. Overall survival, cumulative incidence of relapse and event-free sur-
vival in patients with high-risk acute promyelocytic leukemia. Chemo:
chemotherapy; ATO: arsenic trioxide; CR: complete remission.
due to myelosuppression (the remaining being due to inter-
current disease or secondary AML/MDS).
However, the main result in this standard-risk APL group
was that no relapses were seen in the ATO arm, and that
this relapse rate was significantly lower than in the AraC
and ATRA consolidation arms. These results suggest that
adding ATO to an already highly effective ATRA
chemotherapy regimen may further improve the regimen’s
anti-leukemic effect, and that ATO may not be dispensable
in the treatment of standard-risk APL. On the other hand,
substituting ATO for AraC did not reduce the duration of
neutropenia after consolidation cycles, and neutropenia
was longer with ATO and idarubicin than with ATRA and
idarubicin consolidation cycles. This finding suggests that
ATO, a non-myelosuppressive drug when used alone or
combined with ATRA, may worsen myelosuppression
when used concomitantly with chemotherapy. The dura-
tion of hospitalization was, however, shorter after ATO
and idarubicin than after AraC and idarubicin  consolida-
tion cycles.  The incidence of deaths in complete remission
was not reduced in the ATO group, but only two deaths in
complete remission were attributable to myelosuppression
in the three consolidation arms. Finally, the incidence of
secondary AML/MDS was similar in the three treatment
arms, and similar to that reported in APL patients treated
with ATRA chemotherapy regimens, i.e., between 1% and
2%.20–22 By contrast, in the follow up of the two main clini-
cal trials that used ATRA-ATO regimens without
chemotherapy in newly diagnosed APL, no case of second-
ary AML/MDS has been reported so far (Lo Coco and
Russell, personal communications).
Thus, in standard-risk APL, and in spite of very high com-
plete remission and very low relapse rates obtained with
ATRA chemotherapy combinations, our results confirm
that the rates can be further improved by using ATO during
the consolidation regimen. ATO in this situation did indeed
reduce the relapse risk in standard-risk APL, confirming
results of two recent, large studies.10,11 Long-term results of
one of them, the Italian German study, show in particular
that an ATRA-ATO regimen is not just equivalent but supe-
rior to ATRA chemotherapy regimens in terms of relapse
rate and overall survival. Thus, ATRA-ATO (chemotherapy
free) regimens are becoming reference treatments for stan-
dard-risk APL.
With regards to high-risk APL, only limited studies of
ATO-ATRA regimens without chemotherapy have been
published, and in those studies patients often also received
myelosuppressive drugs, mainly gentuzumab.10,12 In the
British study, this approach was found to give results equiv-
alent to those of an ATRA chemotherapy regimen, but the
overall number of patients included in the randomized study
was only 56.10 A US intergroup study showed that addition
of ATO to a classical ATRA chemotherapy regimen signifi-
cantly reduced the relapse rate. The ATRA chemotherapy
regimen was, however based on daunorubicin instead of
idarubicin (with a total scheduled dose of 500 mg/m2),
which may have contributed to higher relapse rates. 
In the present study, among the patients with high-risk
APL there was a very high complete remission rate (97.4%)
and, contrary to the US intergroup study, a very  low
relapse rate (2.5%) was seen in the chemotherapy consoli-
dation arm (without ATO), confirming our previous
results.23
The fact that substituting ATO for AraC was not associ-
ated with an increased incidence of relapse (5.3% versus
2.7%), but with a reduced incidence of deaths in complete
remission (from 7.8% to 0%) was, therefore, an important
finding. This substitution also lead to less myelosuppres-
sion and less hospitalization for consolidation cycles.
By contrast, the chemotherapy plus ATO consolidation
therapy, combining AraC and ATO, used during the first
part of the trial, did not further reduce the relapse rate
(which was, it should be noted, already very low in the con-
ventional AraC arm) but was associated with increased
myelosuppression and a 5% rate of deaths in complete
remission. This finding supports the fact that ATO worsens
myelosuppression when used concomitantly with
chemotherapy, as in the standard-risk group.
Our results therefore support the addition of ATO during
consolidation cycles, in high-risk APL, at least in order to
reduce the amount of chemotherapy administered and,
therefore, the rate of deaths in complete remission (as in
our study) but also the relapse rate (according to other stud-
ies, including the US intergroup study). While ATO-ATRA
regimens without chemotherapy can now probably be sub-
stituted for ATRA chemotherapy regimens in standard-risk
APL, ongoing clinical trials will show to what extent
chemotherapy can also be reduced or even avoided in high-
risk APL.
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